Results 281 to 290 of about 176,756 (350)

The Homeobox Genes: Classification, Regulation, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Overview of the homeobox gene superfamily and its pathophysiological roles. The homeobox superfamily comprises several major classes, including ANTP, PRD, TALE, LIM, POU, and others. Among these, the HOX clusters (A–D) play critical roles in embryonic development specifically in conferring cellular identity, regulating morphogenesis, and guiding axial ...
Maedeh Dadzadi, Shahin Ramazi, Mona Darvazi, Sepideh Yoosefi, Melika Abbasi, Shirin Farsad   +5 more
wiley   +1 more source

Synaptic potentiation requires PARP1 activation: prevailing concepts are revisited. [PDF]

Mol Psychiatry
Cohen-Armon M, Segal M.
europepmc   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor. [PDF]

Cell Rep Methods
Marks D, Garcia E, Kumar S, Tyson K, Koch C, Ivanov AP, Edel JB, Mirza HB, Flanagan W, Dunsby C, French PMW, McNeish IA.   +11 more
europepmc   +1 more source

Sulforaphane Synergizes With PD‐1 Blockade Through Activating CD8+ T Cells in Non–Small Cell Lung Cancer: Preclinical and Clinical Investigations

MedComm, Volume 7, Issue 4, April 2026.
SFN sensitizes PD‐1 blockade therapy in preclinical and clinical investigations, with no side effects. SFN elevates the antitumor response in peripheral and tumor microenvironment. ABSTRACT Anti‐PD‐1/PD‐L1 therapy has achieved promising success across several tumor types; however, its efficacy is still far from satisfactory in non–small cell lung ...
Jieyao Li, Jinyan Liu, Zheng Wang, Ming Zhao, Mingming You, Ziyi Fu, Caijuan Guo, Tengyue Zhang, Shasha Liu, Dongli Yue, Shuangning Yang, Yixin Li, Qun Gao, Yanfen Liu, Jianmin Huang, Liping Wang, Yi Zhang   +16 more
wiley   +1 more source

Editorial: Overcoming resistance in DDR inhibition: new targets and therapeutic strategies. [PDF]

Front Mol Biosci
Tsai CL, Gonçalves AC, Ahmed Z.
europepmc   +1 more source

The Nexus of Stemness, Telomere Stability, and Metabolic Reprogramming in Glioblastoma: Foundations of Tumor Persistence and Targets for Intervention

MedComm, Volume 7, Issue 4, April 2026.
Integrated schematic depicting the interplay between glioma stem‐like cells, telomere maintenance mechanisms, and metabolic reprogramming in shaping immune suppression and therapeutic resistance in glioblastoma . ABSTRACT Glioblastoma (GBM) is a highly aggressive, therapy‐resistant brain tumor with inevitable recurrence despite maximal multimodal ...
Ji‐Yong Sung, Kihwan Hwang
wiley   +1 more source

Targeting DNA Damage and Repair Pathways in Cerebral Ischemic Stroke: From Bench to Bedside. [PDF]

Transl Stroke Res
Xie Z, Luo Y, Han Z.
europepmc   +1 more source

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, Shrestha R, Aragon-Ching JB, Goswami M, Donahue RN, Cordes LM, Baj A, Seo CCY, Terrigino NT, Bright JR, Hennigan ST, King IM, Trostel SY, Fenimore JM, Liu Y, Calzone KA, Schlom J, Gulley JL, Dahut WL, Figg WD, Sowalsky AG, Lee JM, Karzai F.   +27 more
europepmc   +1 more source

Bifendate inhibits cell PARthanatos by activating the MEK/ERK pathway. [PDF]

Biochem Biophys Rep
Hu AM, Chen M, Zhu CC, Zhu ZM, Xu XH.
europepmc   +1 more source